Domatinostat (4SC-202) is primarily investigated for its potential in cancer therapy, particularly as a histone deacetylase (HDAC) inhibitor. It targets HDACs, which play a role in gene expression regulation, and is studied for its ability to induce cancer cell death and inhibit tumor growth. Research focuses on its use in treating hematologic malignancies and solid tumors, either as a standalone treatment or in combination with other therapies like immunotherapy or chemotherapy. Its role in enhancing immune responses and overcoming resistance to existing treatments is also being explored. Clinical trials are ongoing to evaluate its efficacy and safety in various cancer types.